SAN DIEGO, CA--(Marketwired - Dec 19, 2013) - NuVasive, Inc. (
In early 2013, Paul Kosters was appointed Senior Vice President of EMEA. Kosters' dynamic leadership and regional experience have proven invaluable as NuVasive works to enhance the execution of its market share-taking strategy in EMEA. To further promote that initiative, Kosters will be supported by three key new leaders in Western Europe.
With over 11 years of medical device experience, Frank Middeke has been appointed Managing Director of Germany, Austria, & Switzerland (DACH). Middeke joins NuVasive from DePuy Synthes, where he held various sales and marketing roles in spine with increasing responsibility in Germany, Austria, and Switzerland. Most recently, Middeke was the National Sales Director for the DePuy Joint Reconstruction Unit in Germany.
As well, with over 10 years of experience in the German spine market, Christoph Hoemberg has been appointed Director of Sales in Germany. Hoemberg began his career as a DePuy sales representative in the northern region of Germany where he quickly advanced to his most recent role as Regional Sales Manager for Depuy Synthes and held full responsibility for countrywide pricing and tenders.
In addition to the appointments in Germany, Constantino "Tino" Barros, has been appointed Country Director of Spain. Barros has a decade of management experience in Spain and successfully built high growth spine markets in previous positions with Medtronic and Kyphon. He started his career as a sales representative in spine and quickly worked his way to country manager for Medtronic, responsible for direct and indirect sales teams of over 30 people, product managers, and corporate infrastructure.
"I am exceptionally pleased to welcome Frank, Christoph, and Tino to the NuVasive Family," said Senior Vice President of EMEA, Paul Kosters. "I look forward to their contributions as we collaborate to strengthen the NuVasive footprint in Europe, particularly in the DACH region. Based on the quality of the EMEA team that we now have in place, I am confident that we can work to drive toward market leadership in an area with considerable opportunity."
Russell Powers, Executive Vice President of International said, "We expect international expansion to be a key driver of our evolution into a $1 Billion Start-up™, and we are working to ensure outstanding organizational and operational support overseas. Our strong EMEA team will facilitate the continued execution of NuVasive's global market share taking strategy."
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.6 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties are described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
- Health Care Industry